This grant funds research to develop and advance monoclonal antibody therapies targeting one of six specified Flaviviruses. Activities include in-vitro characterization and in-vivo testing to demonstrate protective efficacy. The goal is to expand therapeutic options for emerging and re-emerging viral infections and strengthen preparedness against epidemics and pandemics through innovative antibody research.
Eligible applicants include legal entities established in EU member states, associated countries, and the United States. Applicants must comply with admissibility conditions, page limits, and layout requirements as specified in the Horizon Europe Work Programme. Specific eligibility details are outl
